WO1999023111A1 - Process for the production of highly viral safe components for forming fibrin glue from a pool of human plasma - Google Patents
Process for the production of highly viral safe components for forming fibrin glue from a pool of human plasma Download PDFInfo
- Publication number
- WO1999023111A1 WO1999023111A1 PCT/CA1998/001008 CA9801008W WO9923111A1 WO 1999023111 A1 WO1999023111 A1 WO 1999023111A1 CA 9801008 W CA9801008 W CA 9801008W WO 9923111 A1 WO9923111 A1 WO 9923111A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solution
- thrombin
- proteins
- precipitate
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0017—Filtration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/908—Mechanical repair performed/surgical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/92—Detection of biochemical
Definitions
- Pasteurization of albumin and IgGs appeared at the beginning of the 50s. This technique, however, was directed to inactivation of hepatitis virus (hepatitis B and non A-non B). Curran et al. (1984) raised the issue of viral transmission of HIV type by transfusion or the use of other blood derivatives, particularly coagulation factors. Since then, methods of viral inactivation focused on HIV. No HIV transmission was signaled from the use of albumin or IgGs, this lack of viral transmission being assigned to the step of pasteurization (Mitra et al. (1986)). Coagulation factors such as factor VIII and IX are widely used by hemophilic patients. Heimburger et al.
- Studies conducted on 29 patients having received these heat-treated products have shown that there was no seroconversion of HIV of HB and that there was a significative reduction of the incidence of transmission of NANBH.
- Other methods of viral inactivation have been developed using a light sources (UV, gamma rays, and laser) to irradiate the infectious agents in plasma.
- step b) is preferably made in 1% Tris and 1.6% sodium citrate pH 6 to 7.3 or pH 9.5 to 10.5 to bring the protein concentration to about 20-22 mg/mL before adding L-Histidine.
- the cation exchange medium is said non-compressible composite medium of sulfoalkyl-activated dextran and silica particles.
- the precipitate obtained rich in fibrinogen, factor XIII and fibronectin, is soiubilized with a buffer containing 1% Tris and 1.6% sodium citrate pH: 6.0 ⁇ 0.1 (pH 7.3 also works).
- the precipitate is soiubilized at room temperature, under agitation.
- the buffer described above is added as needed to get a protein concentration of about 20 - 22 mg/ml.
- L-Histidine is added at the rate of 0.2 - 0.3 g per gram of protein.
- the protein solution is then centrifuged at 10,000 rpm for 20 minutes at about 4° C (Beckman J2-MI, rotor JA-10 type). A lipid layer floating at the surface of the protein solution is removed.
- the protein solution is gently transferred into a beaker and filtered through a 0.2 micron capsule filter (Gelman SuporCap, product N 2 12991 or 12992).
- a quantity of 50 mM amino-6 hexanoic acid is added to the filtrate under agitation and the mixture is incubated at 35° C ⁇ 2° C for about one hour and then cooled down to 0° C ⁇ 2° C.
- a quantity of sodium or potassium phosphate monobasic U.S.P N 2 5,290,91 ⁇ issued to Haemacure Biotech Inc.
- sodium or potassium acetate U.S.P. N 2 5,395,923 issued to Haemacure Biotech Inc.
- Centrifugation The mixture is filtered or centrifuged at 4,200 rmp (Beckman J6-MC, rotor 4.2 type) for 20 minutes at 4° C. The solvent, the detergent and the contaminating proteins are eliminated by centrifugation. The precipitate is recovered and transferred into a beaker.
- the protein solution is filled into 10 ml vials at the rate of 60 ⁇ 5 mg of clotable fibrinogen per vial. Lyophilization:
- the diafiltered thrombin solution is then filtered over a hollow-fiber membrane such as a Planova BMM microporous membrane (Bemberg microporous membrane BMM Development, Asahi Chemical Industries, Tokyo, Japan) comprising a cuprammonium regenerated cellulose fiber having a pore size of about 15 nm.
- a Planova BMM microporous membrane Bemberg microporous membrane BMM Development, Asahi Chemical Industries, Tokyo, Japan
- This technique substantially allows the remove non-lipid-enveloped viruses which cannot be inactivated by SD treatment of the process.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT98951133T ATE305011T1 (en) | 1997-10-30 | 1998-10-29 | METHOD FOR PRODUCING VIRUS-FREE THROMBIN FOR PREPARING FIBRIN GLUE FROM HUMAN PLASMA POOL |
PL98340300A PL194589B1 (en) | 1997-10-30 | 1998-10-29 | Method of obtaining ingredients of high viral safety for use in obtaining fibrinic glue from mixed human blood serum |
JP2000518981A JP4278861B2 (en) | 1997-10-30 | 1998-10-29 | Method for producing fibrin glue-forming component with high safety against virus contamination from human plasma pool |
CA002307380A CA2307380A1 (en) | 1997-10-30 | 1998-10-29 | Process for the production of highly viral safe components for forming fibrin glue from a pool of human plasma |
AU97316/98A AU759145B2 (en) | 1997-10-30 | 1998-10-29 | Process for the production of highly viral safe components for forming fibrin glue from a pool of human plasma |
IL135812A IL135812A (en) | 1997-10-30 | 1998-10-29 | Process for the production of thrombin from plasma |
NZ504246A NZ504246A (en) | 1997-10-30 | 1998-10-29 | Production of virion-free thrombin recovered from whole plasma from which fibrinogen, Factor VIII and fibronectin have been precipitated |
DE69831684T DE69831684T2 (en) | 1997-10-30 | 1998-10-29 | A method of producing high virus free thrombin for preparing fibrin glue from human plasma pool |
EP98951133A EP1027371B1 (en) | 1997-10-30 | 1998-10-29 | Process for the production of highly viral safe thrombin for forming fibrin glue from a pool of human plasma |
NO20002293A NO323299B1 (en) | 1997-10-30 | 2000-04-28 | Process for preparing thrombin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/960,660 US5981254A (en) | 1997-10-30 | 1997-10-30 | Process for producing thrombin from plasma |
US08/960,660 | 1997-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999023111A1 true WO1999023111A1 (en) | 1999-05-14 |
Family
ID=25503448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1998/001008 WO1999023111A1 (en) | 1997-10-30 | 1998-10-29 | Process for the production of highly viral safe components for forming fibrin glue from a pool of human plasma |
Country Status (16)
Country | Link |
---|---|
US (1) | US5981254A (en) |
EP (1) | EP1027371B1 (en) |
JP (1) | JP4278861B2 (en) |
AT (1) | ATE305011T1 (en) |
AU (1) | AU759145B2 (en) |
CA (1) | CA2307380A1 (en) |
DE (1) | DE69831684T2 (en) |
DK (1) | DK1027371T3 (en) |
ES (1) | ES2249843T3 (en) |
IL (1) | IL135812A (en) |
IN (1) | IN185759B (en) |
NO (1) | NO323299B1 (en) |
NZ (1) | NZ504246A (en) |
PL (1) | PL194589B1 (en) |
RU (1) | RU2236237C2 (en) |
WO (1) | WO1999023111A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001048016A1 (en) * | 1999-12-23 | 2001-07-05 | Csl Limited | Separation of fibrinogen from plasma proteases |
JP2002114799A (en) * | 2000-08-01 | 2002-04-16 | Nihon Pharmaceutical Co Ltd | Method for removing virus |
EP1250929A1 (en) * | 1999-12-20 | 2002-10-23 | Mitsubishi Pharma Corporation | Virus-free plasma protein compositions treated with porous membrane and process for producing the same |
EP1348445A1 (en) * | 2002-03-15 | 2003-10-01 | Aventis Behring GmbH | Method for separating viruses from a protein solution by nanofiltration |
EP1457497A1 (en) * | 2003-03-06 | 2004-09-15 | Probitas Pharma, S.A. | Process for removing viruses in fibrinogen solutions and fibrinogen obtained by said process |
AU779126B2 (en) * | 1999-12-23 | 2005-01-06 | Csl Limited | Separation of fibrinogen from plasma proteases |
EP1649867A1 (en) | 2004-10-22 | 2006-04-26 | Grifols, S.A. | Stable thrombin composition |
US7816495B2 (en) | 2002-07-10 | 2010-10-19 | Nhs Blood And Transplant | Processes for the preparation of fibrinogen |
US8598319B2 (en) | 2005-06-29 | 2013-12-03 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Process for separating proteins fibrinogen, factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilised concentrates of said proteins |
EP2329019B1 (en) * | 2008-08-08 | 2014-03-12 | Cambridge Enterprise Limited | Isolation of nucleic acid |
US9011846B2 (en) | 2011-05-02 | 2015-04-21 | Biomet Biologics, Llc | Thrombin isolated from blood and blood fractions |
WO2023020914A1 (en) | 2021-08-18 | 2023-02-23 | Biotest Ag | Dry heat treatment of plasma-derived factor viii |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT407484B (en) * | 1997-11-12 | 2001-03-26 | Bio Prod & Bio Eng Ag | MEDICINES FOR PROMOTING Wound Healing |
US7411006B2 (en) | 2000-10-23 | 2008-08-12 | Shanbrom Technologies, Llc | Enhanced production of blood clotting factors and fibrin fabric |
US7365173B2 (en) * | 2002-02-04 | 2008-04-29 | American National Red Cross | Method for the production of pure virally inactivated butyrylcholinesterase |
US20070015230A1 (en) * | 2002-04-15 | 2007-01-18 | Hammond David J | Identification and characterization of analytes from whole blood |
US20060275753A1 (en) * | 2002-04-15 | 2006-12-07 | Hammond David J | Recovery of analytes using combinatorial libraries |
AU2003231731A1 (en) * | 2002-04-15 | 2003-11-03 | American National Red Cross | Method for detecting ligands and targets in a mixture |
US20060275829A1 (en) * | 2002-04-15 | 2006-12-07 | Hammond David J | Combinatorial library for proteomic investigations |
WO2004011023A1 (en) * | 2002-07-23 | 2004-02-05 | Bio-Products & Bio-Engineering Aktiengesellschaft | Pharmaceutically active substance preparations and drugs that are capable of generating thrombin and/or that contain thrombin |
CN1890257A (en) * | 2003-12-01 | 2007-01-03 | 诺和诺德医疗保健公司 | Virus filtration of liquid factor vii compositions |
WO2006009989A1 (en) * | 2004-06-22 | 2006-01-26 | Zymogenetics, Inc. | Thrombin compositions |
DE102004044429B4 (en) * | 2004-09-14 | 2009-04-30 | Biotest Ag | Process for the preparation of a composition containing von Willebrand factor |
US20060270015A1 (en) * | 2005-05-26 | 2006-11-30 | Dan Pawlak | Thrombin purification |
US20120195953A1 (en) * | 2007-09-19 | 2012-08-02 | Kieu Hoang | Fibrin sealant (FIBRINGLURAAS) consisting of a kit of lyophilized high concentrate fribinogen intentionally enriched and preserved with fibronolysis inhibitor A1AT |
WO2014049063A1 (en) * | 2012-09-26 | 2014-04-03 | Bone Therapeutics S.A. | Formulations involving solvent/detergent-treated plasma (s/d plasma) and uses thereof |
RU2583931C2 (en) * | 2014-06-11 | 2016-05-10 | Федеральное государственное бюджетное учреждение Гематологический научный центр Министерства здравоохранения РФ | Method of producing thrombin concentrate |
US9932388B2 (en) | 2014-11-13 | 2018-04-03 | Hemarus Therapeutics Limited | Chromatographic process for producing high purity fibrinogen and thrombin |
JP6666757B2 (en) * | 2016-03-10 | 2020-03-18 | 日本メジフィジックス株式会社 | Method for quantifying polyoxyethylene nonionic surfactant and method for producing radiopharmaceutical preparation |
EP3755455A1 (en) * | 2018-02-19 | 2020-12-30 | Bayer HealthCare, LLC | Modified filter membrane and method |
WO2020229521A1 (en) | 2019-05-14 | 2020-11-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for inhibiting or reducing bacterial biofilms on a surface |
CN113754757B (en) * | 2021-07-01 | 2024-06-14 | 华兰生物工程股份有限公司 | Preparation method of human fibrinogen |
KR20230121373A (en) * | 2022-02-11 | 2023-08-18 | 주식회사 녹십자 | Method for Purifying Factor XIII |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5290918A (en) * | 1993-02-23 | 1994-03-01 | Haemacure Biotech Inc. | Process for the obtention of a biological adhesive made of concentrated coagulation factors by acidic precipitation |
US5395923A (en) * | 1993-02-23 | 1995-03-07 | Haemacure-Biotech, Inc. | Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out" |
WO1996009376A1 (en) * | 1994-09-21 | 1996-03-28 | Haemacure Biotech Inc. | Therapeutic grade thrombin production and products |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3843126C3 (en) * | 1988-12-22 | 1994-10-06 | Octapharma Ag | Process for the production of a high-purity thrombin concentrate |
FR2679251B1 (en) * | 1991-07-18 | 1993-11-12 | Nord Assoc Essor Transfusion San | PROCESS FOR THE PREPARATION OF A HUMAN THROMBIN CONCENTRATE FOR THERAPEUTIC USE. |
-
1997
- 1997-10-30 US US08/960,660 patent/US5981254A/en not_active Expired - Fee Related
-
1998
- 1998-10-29 PL PL98340300A patent/PL194589B1/en not_active IP Right Cessation
- 1998-10-29 ES ES98951133T patent/ES2249843T3/en not_active Expired - Lifetime
- 1998-10-29 IN IN1927CA1998 patent/IN185759B/en unknown
- 1998-10-29 AU AU97316/98A patent/AU759145B2/en not_active Ceased
- 1998-10-29 DK DK98951133T patent/DK1027371T3/en active
- 1998-10-29 IL IL135812A patent/IL135812A/en not_active IP Right Cessation
- 1998-10-29 RU RU2000113224/15A patent/RU2236237C2/en not_active IP Right Cessation
- 1998-10-29 WO PCT/CA1998/001008 patent/WO1999023111A1/en active IP Right Grant
- 1998-10-29 JP JP2000518981A patent/JP4278861B2/en not_active Expired - Fee Related
- 1998-10-29 AT AT98951133T patent/ATE305011T1/en not_active IP Right Cessation
- 1998-10-29 DE DE69831684T patent/DE69831684T2/en not_active Expired - Lifetime
- 1998-10-29 NZ NZ504246A patent/NZ504246A/en unknown
- 1998-10-29 EP EP98951133A patent/EP1027371B1/en not_active Expired - Lifetime
- 1998-10-29 CA CA002307380A patent/CA2307380A1/en not_active Abandoned
-
2000
- 2000-04-28 NO NO20002293A patent/NO323299B1/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5290918A (en) * | 1993-02-23 | 1994-03-01 | Haemacure Biotech Inc. | Process for the obtention of a biological adhesive made of concentrated coagulation factors by acidic precipitation |
US5395923A (en) * | 1993-02-23 | 1995-03-07 | Haemacure-Biotech, Inc. | Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out" |
WO1996009376A1 (en) * | 1994-09-21 | 1996-03-28 | Haemacure Biotech Inc. | Therapeutic grade thrombin production and products |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1250929A1 (en) * | 1999-12-20 | 2002-10-23 | Mitsubishi Pharma Corporation | Virus-free plasma protein compositions treated with porous membrane and process for producing the same |
EP1250929A4 (en) * | 1999-12-20 | 2004-12-29 | Mitsubishi Pharma Corp | Virus-free plasma protein compositions treated with porous membrane and process for producing the same |
US6960463B2 (en) | 1999-12-23 | 2005-11-01 | Csl Limited | Separation of fibrinogen from plasma proteases |
JP2003518513A (en) * | 1999-12-23 | 2003-06-10 | シーエスエル、リミテッド | Separation of fibrinogen from plasma protease |
JP4660048B2 (en) * | 1999-12-23 | 2011-03-30 | シーエスエル、リミテッド | Separation of fibrinogen from plasma protease |
WO2001048016A1 (en) * | 1999-12-23 | 2001-07-05 | Csl Limited | Separation of fibrinogen from plasma proteases |
AU779126B2 (en) * | 1999-12-23 | 2005-01-06 | Csl Limited | Separation of fibrinogen from plasma proteases |
JP2002114799A (en) * | 2000-08-01 | 2002-04-16 | Nihon Pharmaceutical Co Ltd | Method for removing virus |
AU2003200981B2 (en) * | 2002-03-15 | 2008-11-20 | Csl Behring Gmbh | Method for separating off viruses from a protein solution by means of nanofiltration |
US7919592B2 (en) | 2002-03-15 | 2011-04-05 | Zlb Behring Gmbh | Method for separating off viruses from a protein solution by means of nanofiltration |
EP1348445A1 (en) * | 2002-03-15 | 2003-10-01 | Aventis Behring GmbH | Method for separating viruses from a protein solution by nanofiltration |
KR100998158B1 (en) | 2002-03-15 | 2010-12-06 | 체에스엘 베링 게엠베하 | Method for separating off viruses from a protein solution by means of nanofiltration |
US7816495B2 (en) | 2002-07-10 | 2010-10-19 | Nhs Blood And Transplant | Processes for the preparation of fibrinogen |
AU2004200745B8 (en) * | 2003-03-06 | 2009-01-08 | Grifols, S.A. | Process for Removing Viruses in Fibrinogen Solutions and Fibrinogen Obtained by Said Process |
EP1457497A1 (en) * | 2003-03-06 | 2004-09-15 | Probitas Pharma, S.A. | Process for removing viruses in fibrinogen solutions and fibrinogen obtained by said process |
US7442308B2 (en) | 2003-03-06 | 2008-10-28 | Grifols, S.A. | Process for removing viruses in fibrinogen solutions and fibrinogen obtained by said process |
AU2004200745B2 (en) * | 2003-03-06 | 2008-07-03 | Grifols, S.A. | Process for Removing Viruses in Fibrinogen Solutions and Fibrinogen Obtained by Said Process |
EP1649867A1 (en) | 2004-10-22 | 2006-04-26 | Grifols, S.A. | Stable thrombin composition |
US9376674B2 (en) | 2004-10-22 | 2016-06-28 | Grifols, S.A. | Process to prepare a stable thrombin composition |
EP2772499A1 (en) | 2005-06-29 | 2014-09-03 | Laboratoire Français du Fractionnement et des Biotechnologies | Separation of plasma proteins |
US9320779B2 (en) | 2005-06-29 | 2016-04-26 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Process for separating proteins fibrinogen, factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilised concentrates of said proteins |
US9339530B2 (en) | 2005-06-29 | 2016-05-17 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Process for separating proteins fibrinogen, factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilised concentrates of said proteins |
US8598319B2 (en) | 2005-06-29 | 2013-12-03 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Process for separating proteins fibrinogen, factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilised concentrates of said proteins |
EP2329019B1 (en) * | 2008-08-08 | 2014-03-12 | Cambridge Enterprise Limited | Isolation of nucleic acid |
US9422543B2 (en) | 2008-08-08 | 2016-08-23 | Cambridge Enterprise Limited | Isolation of nucleic acid |
US9011846B2 (en) | 2011-05-02 | 2015-04-21 | Biomet Biologics, Llc | Thrombin isolated from blood and blood fractions |
WO2023020914A1 (en) | 2021-08-18 | 2023-02-23 | Biotest Ag | Dry heat treatment of plasma-derived factor viii |
Also Published As
Publication number | Publication date |
---|---|
EP1027371B1 (en) | 2005-09-21 |
DE69831684T2 (en) | 2006-06-22 |
NO20002293D0 (en) | 2000-04-28 |
JP4278861B2 (en) | 2009-06-17 |
RU2236237C2 (en) | 2004-09-20 |
DE69831684D1 (en) | 2006-02-02 |
NO323299B1 (en) | 2007-03-05 |
PL340300A1 (en) | 2001-01-29 |
JP2001521941A (en) | 2001-11-13 |
CA2307380A1 (en) | 1999-05-14 |
EP1027371A1 (en) | 2000-08-16 |
NZ504246A (en) | 2002-09-27 |
IL135812A (en) | 2007-09-20 |
AU9731698A (en) | 1999-05-24 |
DK1027371T3 (en) | 2006-01-09 |
AU759145B2 (en) | 2003-04-03 |
NO20002293L (en) | 2000-06-30 |
IN185759B (en) | 2001-04-21 |
US5981254A (en) | 1999-11-09 |
PL194589B1 (en) | 2007-06-29 |
ATE305011T1 (en) | 2005-10-15 |
ES2249843T3 (en) | 2006-04-01 |
IL135812A0 (en) | 2001-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5981254A (en) | Process for producing thrombin from plasma | |
CA1329542C (en) | Plasma and recombinant protein formulations in low ionic strength media | |
US5099003A (en) | Method of preparing a sterile plasma-protein solution containing fibrinogen and factor xiii | |
CA2201714C (en) | Method for isolation of highly pure von willebrand factor | |
AU2006202680B2 (en) | Process for separating proteins fibrinogen, factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilised concentrates of said proteins | |
JP3628703B2 (en) | Therapeutic grade thrombin products and products | |
JP4324102B2 (en) | Method for preparing fibrinogen | |
AU549584B2 (en) | Heat stabilization of plasma proteins | |
JP4925822B2 (en) | Method for stabilizing plasma protein cryoprecipitates for use in virus-inactivated heat treatment | |
FI81363C (en) | FOERFARANDE FOER PASTOERISERING AV PREPARAT AV BLODKOAGULERINGSFAKTORERNA II, VII, IX OCH X. | |
IE842180L (en) | Pasteurization of human plasma | |
MX2007014571A (en) | Thrombin purification. | |
WO1998030230A1 (en) | Protein-containing compositions and process for producing the same | |
RU2045902C1 (en) | Method for stabilization of blood plasma during pasteurization and method for pasteurization of blood plasma | |
AU756017B2 (en) | The process of preparing immunoglobulin for intravenous injection by viruses double-sterilized without adding any protectant | |
JPS59167519A (en) | Removal of fibrinogen from mixed serum proteins with deactivated thrombin gel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2307380 Country of ref document: CA Kind code of ref document: A Ref document number: 2307380 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 504246 Country of ref document: NZ |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 97316/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998951133 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998951133 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 97316/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998951133 Country of ref document: EP |